Korea Investment CORP Boosts Stock Position in Cencora, Inc. (NYSE:COR)

Korea Investment CORP lifted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 5.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 130,637 shares of the company's stock after buying an additional 6,600 shares during the quarter. Korea Investment CORP owned about 0.07% of Cencora worth $29,352,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of COR. JFS Wealth Advisors LLC lifted its holdings in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after acquiring an additional 46 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in Cencora during the 4th quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC raised its position in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co bought a new stake in shares of Cencora in the 4th quarter valued at about $33,000. Finally, WASHINGTON TRUST Co raised its position in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Finally, Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus target price of $280.20.

Insiders Place Their Bets

In related news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This trade represents a 21.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,675 shares of company stock worth $8,034,778 over the last 90 days. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Performance

Shares of COR traded up $1.76 during mid-day trading on Wednesday, hitting $279.17. The stock had a trading volume of 285,311 shares, compared to its average volume of 1,569,432. The business has a fifty day moving average price of $255.18 and a 200-day moving average price of $241.79. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $280.70. The firm has a market cap of $54.13 billion, a P/E ratio of 39.71, a PEG ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.79%. Cencora's payout ratio is 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.